Research programme: peripheral arterial disorders therapy - Integene International
Latest Information Update: 13 May 2014
At a glance
- Originator Integene International
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Peripheral arterial disorders